• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2022 NIHR Health Technology Assessment programme Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling
2022 NIHR Public Health Research (PHR) programme E-health interventions targeting STIs, sexual risk, substance use and mental health among men who have sex with men: four systematic reviews
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of medical care and services in long-term care facilities]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: a look at Québec’s family medicine groups and a proposal to segment the population to support continuous quality improvement approaches based on health needs]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of care and services for the prevention and management of post COVID-19 conditions]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: practices for screening or reducing psychological symptoms in individuals with a post-COVID-19 condition]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: primary care and service quality indicators for supporting continuous quality improvement in Québec’s family medicine groups]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: cervical cancer screening in Québec - recommendations for implementing the human papillomavirus detection test (HPV test) as the primary screening test]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: optimal use of cardiac ultrasound in Québec - diagnosing patients with a murmur and monitoring patients with valve diseases (native and prosthetic valves)]
2022 NIHR Health Technology Assessment programme Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: classification of thickened liquids for dysphagia]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of HyQvia™ (human normal immunoglobulin 10% and hyaluronidase) – primary and secondary immunodeficiency]
2022 Health Information and Quality Authority (HIQA) Descriptive analysis of COVID-19 epidemiological indicators and associated contextual factors in European countries
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Blinatumomab (new therapeutic indication: acute lymphoblastic B-cell leukaemia, high-risk first relapse, Ph-, CD19+, ≥1 and <18 years)]
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Migalastat (new therapeutic indication: Fabry disease, 12 to < 16 years)]
2022 The Federal Joint Committee (G-BA) Pharmaceutical Directive/Annex XII: Odevixibat (progressive familial intrahepatic cholestasis)
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: circulating tumour DNA (liquid biopsy)-based EGFR exon 20 T790M mutation detection in advanced non-small cell lung cancer after previous EGFR-directed therapy]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: profile of individuals with a history of cancer infected with SARS-CoV-2 during the first two waves of the pandemic]
2022 Norwegian Institute of Public Health (NIPH) [Operating room ventilation: a health technology assessment]
2022 Norwegian Institute of Public Health (NIPH) Molecular tests for detection of PIK3CA mutations in men and postmenopausal women with HR+/HER2–, locally advanced or metastatic breast cancer: a health technology assessment
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tafasitamab (diffuse large B-cell lymphoma (DLBCL), combination with lenalidomide)]
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Selumetinib (neurofibromatosis (≥ 3 to < 18 years, type 1))]
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Vosoritide (achondroplasia, ≥ 2 years)]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: immunoglobulin shortage: alternative treatments to nonspecific human immunoglobulins]
2022 Penn Medicine Center for Evidence-based Practice (CEP) Breast cancer risk assessment tools
2022 Penn Medicine Center for Evidence-based Practice (CEP) Testosterone reference ranges for gender diverse individuals
2022 Penn Medicine Center for Evidence-based Practice (CEP) Structured screening questionnaires for alcohol misuse/alcohol use disorders
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: updated recommendations for adjusting antidiabetic medication in type 2 diabetes]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating pharmacological treatment for oropharyngeal mucositis in a patient receiving cancer therapy]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: intravenous iron therapy in adults]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of the relevance of newborn screening for severe combined immunodeficiency SCID]
2022 Penn Medicine Center for Evidence-based Practice (CEP) Clinical utility of inpatient fall risk assessment
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of insulin pump systems for type 1 diabetes patients]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: relevance of the prerequisite of the use of an immunosuppressant drug for the coverage of biologic agents (gastroenterology and dermatology)]
2022 Austrian Institute for Health Technology Assessment (AIHTA) CAR-T cell-therapies in development, update 2022
2022 Austrian Institute for Health Technology Assessment (AIHTA) Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries
2022 Austrian Institute for Health Technology Assessment (AIHTA) [Telemonitoring in Austrian diabetes care: a systematic analysis of evaluation methodologies]
2022 NIHR Health Services and Delivery Research programme Components of interventions to reduce restrictive practices with children and young people in institutional settings: the Contrast systematic mapping review
2022 NIHR Health Services and Delivery Research programme Assessment and management pathways of older adults with mild cognitive impairment: descriptive review and critical interpretive synthesis
2022 Ontario Health Transcatheter valve-in-valve implantation for degenerated mitral or tricuspid bioprosthetic valves: a health technology assessment
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: high-dose vitamin C injections for cancer patients in Quebec]
2022 Austrian Institute for Health Technology Assessment (AIHTA) ATMPs and gene therapies in development. Horizon scanning – update 2022
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of lung cancer in the Québec context]
2022 Health Information and Quality Authority (HIQA) High level review of configuration and reform of public health systems in selected countries
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: needs of children at-risk or in situation of neglect and those of their family]
2022 Penn Medicine Center for Evidence-based Practice (CEP) Patient bias against healthcare providers
2022 Ontario Health First-trimester screening program for the risk of pre-eclampsia using a multiple-marker algorithm: a health technology assessment
2022 Andalusian Health Technology Assessment Area (AETSA) Electro-hipertermia modulada en pacientes con cáncer de páncreas, cáncer colorrectal avanzado y gliomas malignos
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: solid organ transplantation – Section 1 - overview of heart and lung transplantation in Québec]
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ixazomib (reassessment after the deadline: multiple myeloma, at least 1 prior therapy, combination with lenalidomide and dexamethasone)]
2022 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Delamanid (repeal of the exemption: pulmonary multi-drug resistant tuberculosis, ≥ 10 kg)]
2022 NIHR Health Services and Delivery Research programme Safety of disinvestment in mid- to late-term follow-up post primary hip and knee replacement: the UK SAFE evidence synthesis and recommendations
2022 Scottish Health Technologies Group (SHTG) vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2022 Agency for Care Effectiveness (ACE) Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022 Agency for Care Effectiveness (ACE) Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022 Agency for Care Effectiveness (ACE) Caption guidance to guide image acquisition in point-of-care echocardiography for patients with cardiovascular disease
2022 Agency for Care Effectiveness (ACE) The PrecivityAD test for the prognosis of Alzheimer's disease
2022 Agency for Care Effectiveness (ACE) Artificial intelligence and its clinical applications
2022 Agency for Care Effectiveness (ACE) 3D printing and its clinical applications
2022 Agency for Care Effectiveness (ACE) Overview of clinical applications of telemedicine
2022 Agency for Care Effectiveness (ACE) Bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears
2022 Agency for Care Effectiveness (ACE) Percutaneous vertebral augmentation systems for treating patients with vertebral compression fractures
2022 Agency for Care Effectiveness (ACE) Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes
2022 Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with conductive or mixed hearing loss
2022 Agency for Care Effectiveness (ACE) Active middle ear implants for patients with hearing loss
2022 Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with single sided deafness
2022 Agency for Care Effectiveness (ACE) Coronary intravascular lithotripsy for patients with severely calcified, stenotic de novo coronary artery
2022 Agency for Care Effectiveness (ACE) Denosumab for treating osteoporosis and glucocorticoid-associated bone loss
2022 Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
2022 Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism
2022 Agency for Care Effectiveness (ACE) Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
2022 Agency for Care Effectiveness (ACE) Infliximab biosimilar for treating inflammatory conditions
2022 Agency for Care Effectiveness (ACE) Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
2022 Agency for Care Effectiveness (ACE) Disease-modifying therapies for treating multiple sclerosis
2022 Agency for Care Effectiveness (ACE) Review of cancer drugs for acute lymphoblastic leukaemia
2022 Agency for Care Effectiveness (ACE) Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease
2022 Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors, immune checkpoint inhibitors and everolimus for treating advanced renal cell cancer
2022 Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced gastric cancer
2022 Agency for Care Effectiveness (ACE) Update of MOH list of subsidised drugs to include treatments for various cancer conditions
2022 Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating ALK mutation-positive advanced non-small-cell lung cancer
2022 Agency for Care Effectiveness (ACE) Review of cancer drugs for prostate cancer
2022 Agency for Care Effectiveness (ACE) Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
2022 Agency for Care Effectiveness (ACE) Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours
2022 Agency for Care Effectiveness (ACE) Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
2022 Agency for Care Effectiveness (ACE) Eltrombopag for treating immune thrombocytopenia and severe aplastic anaemia
2022 Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating differentiated thyroid cancer
2022 Agency for Care Effectiveness (ACE) Immune checkpoint inhibitors and BRAK/MEK inhibitors for treating advanced malignant melanoma
2022 Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated multiple myeloma
2022 Agency for Care Effectiveness (ACE) Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours
2022 Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma
2022 Agency for Care Effectiveness (ACE) Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
2022 Agency for Care Effectiveness (ACE) Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer
2022 Agency for Care Effectiveness (ACE) Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
2022 Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced hepatocellular carcinoma
2022 Agency for Care Effectiveness (ACE) High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
2022 Agency for Care Effectiveness (ACE) Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
2022 Agency for Care Effectiveness (ACE) Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
2022 Agency for Care Effectiveness (ACE) Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension
2022 Agency for Care Effectiveness (ACE) PARP inhibitors and bevacizumab for treating advanced ovarian cancer
2022 Agency for Care Effectiveness (ACE) Bevacizumab biosimilar for treating different types of cancers